Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

OTC Medicines

This article was originally published in SRA

Executive Summary

Revision of AGRD2 proceeds with supplement 4 on efficacy and safety

Revision of AGRD2 proceeds with supplement 4 on efficacy and safety

The Therapeutic Goods Administration has issued the fourth in a series of supplements revising the Australian Guidelines for the Registration of Drugs, Volume 2 (AGRD2) related to OTC medicines 1. Supplement 4: Efficacy and Safety of OTC Medicines supersedes Chapters 9 (safety) and 10 (efficacy) of AGRD2 and must be read in conjunction with other chapters of the document. Supplements 1-3 have been published previously2.

References

1. Australian Guidelines for the Registration of Drugs, Volume 2, Supplement 4: Efficacy and Safety of OTC Medicines, December 2002

2. The Regulatory Affairs Journal , 2002, 13 (6), 509

Latest Headlines
See All
UsernamePublicRestriction

Register

PS108856

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel